| DIRECT COMPETITOR COMPARISON | |
| BMRN | ALTU | ENZN | SHPGY | Industry | | Market Cap: | 1.66B | N/A | 462.28M | N/A | 100.26M | | Employees: | 649 | N/A | 351 | N/A | 65 | | Qtrly Rev Growth (yoy): | 11.20% | N/A | -8.60% | N/A | 19.70% | | Revenue (ttm): | 336.85M | N/A | 188.84M | N/A | 14.05M | | Gross Margin (ttm): | 48.27% | N/A | 73.98% | N/A | 65.67% | | EBITDA (ttm): | 62.97M | N/A | 23.42M | N/A | -12.30M | | Oper Margins (ttm): | 12.50% | N/A | 2.26% | N/A | -137.11% | | Net Income (ttm): | 19.31M | N/A | 781.00K | N/A | N/A | | EPS (ttm): | 0.186 | N/A | 0.017 | N/A | -0.32 | | P/E (ttm): | 88.49 | N/A | 598.24 | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | N/A | 2.2 | 1.31 | | P/S (ttm): | 5.04 | N/A | 2.50 | N/A | 9.43 |
|
| ALTU = Altus Pharmaceuticals Inc. | | ENZN = Enzon Pharmaceuticals Inc. | | SHPGY = Shire plc | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | SHPGY | | SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Fri, Nov 27 -
EDGAR Online | | • | SHPGY | | Shire's Gaucher Candidate Seeks EU Nod
Wed, Nov 25 -
Zacks.com | | • | SHPGY | | Shire moves to advance Gaucher drug
Tue, Nov 24 -
at bizjournals.com | | • | SHPGY | | Biotech Stocks: Shire climbs, Pfizer falls in early trading
Tue, Nov 24 -
at MarketWatch | | • | SHPGY | | Shire applies for Euro approval of Gaucher drug
Tue, Nov 24 -
at MarketWatch | | • | SHPGY | | Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Tue, Nov 24 -
PR Newswire | | • | ENZN | | Enzon Presents Data at 2009 EORTC Meeting
Thu, Nov 19 -
Business Wire | | • | ENZN | | Klarman, Whitman Are Sellers But Witmer Buys in Q3 2009
Wed, Nov 18 -
at Seeking Alpha | | • | ENZN | | Enzon to Present Data at EORTC-NCI-AACR
Mon, Nov 16 -
Business Wire | | • | ENZN | | Unique Strategy Generates Big Returns for Baupost
Fri, Nov 13 -
Indie Research | | • | ENZN | | Watching Klarman's Latest Biotech Play
Thu, Nov 12 -
RealMoney by TheStreet.com | | • | ENZN | | ENZON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
Thu, Nov 12 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
